Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Coloplast delivers 8% organic growth and solid performance across all business areas | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 14 Aug 2019 | Back to overview list |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In addition to solid organic revenue growth, EBIT increased by 13% to DKK 1,438m, corresponding to an EBIT margin of 31%, in the third quarter of the 2018/19 financial year. The company maintains its financial guidance for 2018/19. “We see strong performance in Europe driven by all business areas, double-digit growth in the US, and improved momentum in Emerging Markets driven by solid performance in China. Finally, I would like to highlight our 8% organic growth, year to date, in our Wound Care business and our double-digit growth, year to date, in the Interventional Urology business,” says CEO Kristian Villumsen, Coloplast, and continues: “We deliver solid growth rates across all business areas, driven by our product launches and commercial investments, and we continue to invest in commercial initiatives to drive future growth.” Organic growth rates by business area in the third quarter were 8% in Ostomy Care, 7% in Continence Care, 10% in Interventional Urology, and 7% in Wound & Skin Care. Looking at sales by geographies in the third quarter, the European markets contributed with 5% growth, Other developed markets delivered 12% revenue growth, and Emerging Markets provided a 14% increase. EBIT amounted to DKK 4,077m for the first nine months, an 11% increase in DKK, corresponding to an EBIT margin of 31% against 30% last year. ROIC after tax before special items was 45% in the first nine months against 42% in the same period last year. French price reform Unchanged financial guidance for 2018/19
Attachment |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |